GlassScriptPhysician profile
Patricia K Sun
NPI 1366626426
$1,825.00
in general payments reported to CMS, 2019-2025
20 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.66 · 2020: $17.61 · 2021: $332 · 2022: $177 · 2023: $407 · 2024: $388 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.34 |
| Education | $110.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.77 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Janssen Biotech, INC. | $234.79 | 2021-2024 | Stelara, Tremfya |
| Celgene Corporation | $134.46 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $134.13 | 2023-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $117.52 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.93 | 2021-2024 | Trulance, Xifaxan, Uceris |
| Intercept Pharmaceuticals, INC. | $99.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.61 | 2019-2025 | Eohilia |
| Celltrion USA INC. | $53.49 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $38.53 | 2025 | Dupixent |
| Amgen INC. | $37.46 | 2021 | |
| Madrigal Pharmaceuticals | $36.90 | 2025 | Rezdiffra |
| Lilly USA, LLC | $25.98 | 2024 | Omvoh |
| Mauna Kea Technologies, INC. | $22.79 | 2021 | |
| Allergan, INC. | $19.21 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $15.55 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.25 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $13.07 | 2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $12.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,835.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.